Physician profile
Arletty D Smith
NPI 1699777342
$3,527.54
in general payments reported to CMS, 2019-2025
23 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.42 · 2021: $174 · 2022: $419 · 2023: $582 · 2024: $1,192 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,796 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,795.67 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $969.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $473.19 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Abbott Laboratories | $470.09 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $304.91 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $271.29 | 2023-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $245.84 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $242.35 | 2020-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $97.07 | 2022-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $74.72 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.02 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $49.83 | 2022-2025 | Rexulti |
| Pfizer INC. | $43.28 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $40.22 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $32.53 | 2021 | |
| Photonicare INC | $22.40 | 2025 | Otosight Middle Ear Scope |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.09 | 2024 | Intellis Adaptivestim |
| Axonics, INC. | $18.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.54 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $17.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.32 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.18 | 2024 | |
| Ibsa Pharma INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arletty Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.